Vivos Therapeutics
VVOS
29 hedge funds and large institutions have $5.02M invested in Vivos Therapeutics in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 11 closing their positions.
7% more call options, than puts
Call options by funds: $278K | Put options by funds: $260K
0.01% less ownership
Funds ownership: 0.4% → 0.39% (-0.01%)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
22% less funds holding
Funds holding: 37 → 29 (-8)
45% less capital invested
Capital invested by funds: $9.14M → $5.02M (-$4.12M)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$832K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$394K |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$198K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$148K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIA
Avalon Investment & Advisory
Houston,
Texas
|
-$1.01M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$171K |
| 3 |
AI
Aperture Investors
New York
|
-$143K |
| 4 |
VF
Virtu Financial
New York
|
-$143K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$139K |
VVOS Hedge Fund Activity: Q4 2021 in Review
29 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q4 2021, worth a combined $5.02M — down 45% from $9.14M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VVOS and 3 opened new positions — a net loss of 8 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Russell Investments Group, adding an estimated $832K. The largest seller was Avalon Investment & Advisory, cutting an estimated $1.01M.
- 29 institutional investors held Vivos Therapeutics (VVOS) as of Q4 2021, down from 37 in Q3 2021.
- Funds reported $5.02M of Vivos Therapeutics stock for Q4 2021, down 45% quarter-over-quarter.
- 3 funds opened new Vivos Therapeutics positions in Q4 2021 and 11 closed out, a net change of -8 holders.
- The largest Vivos Therapeutics buyer in Q4 2021 was Russell Investments Group, an estimated $832K added.
- The largest Vivos Therapeutics seller in Q4 2021 was Avalon Investment & Advisory, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2021.